Hydroxyzine Dosing for Anxiety
For anxiety in adults, hydroxyzine is dosed at 50-100 mg orally or intramuscularly as needed, with elderly patients requiring dose reduction to 25-50 mg due to increased risk of sedation and confusion. The evidence base for hydroxyzine in anxiety comes primarily from FDA labeling and clinical trials in generalized anxiety disorder, though notably, current clinical guidelines favor benzodiazepines over hydroxyzine for acute anxiety management.
Standard Adult Dosing
For psychiatric and emotional emergencies including anxiety, the FDA-approved dosing is 50-100 mg intramuscularly stat, repeated every 4-6 hours as needed 1. For oral administration in generalized anxiety disorder, clinical trials have established 50 mg/day as the effective dose, demonstrating superiority over placebo from the first week of treatment 2, 3.
The 50 mg daily dose showed:
- Significant anxiety reduction by week 1 that persisted through 4-12 weeks of treatment
- No rebound anxiety or withdrawal symptoms upon abrupt discontinuation
- Comparable efficacy to bromazepam 6 mg/day over 3 months 2
Elderly Patient Adjustments
Elderly patients require substantial dose reduction, starting at the low end of the dosing range (25-50 mg) with careful monitoring 1. The FDA label explicitly warns that sedating drugs cause confusion and over-sedation in the elderly, who should be started on low doses and observed closely 1.
Key considerations for elderly patients:
- Start with 25 mg doses rather than standard 50-100 mg
- Increased risk of falls, confusion, and cognitive impairment
- Greater frequency of decreased hepatic, renal, or cardiac function
- One study in elderly subjects showed that hydroxyzine 25 mg preserved memory and attention better than lorazepam 1 mg, though minimal sedation still occurred 4
Hepatic Impairment
Patients with hepatic impairment require dose reduction, though specific dosing adjustments are not well-defined in the FDA label 1. Critical pharmacokinetic data from patients with primary biliary cirrhosis reveals:
- Elimination half-life increases dramatically to 36.6 hours (vs. normal ~20 hours) 5
- Clearance is significantly impaired at 8.65 mL/min/kg
- Sedation occurs in all patients and lasts 0.5-6 hours
- Additional adverse effects include blurred vision, dizziness, and dry mouth 5
For hepatic impairment, start with 25 mg doses and extend dosing intervals beyond the standard every 4-6 hours, potentially to once daily given the prolonged half-life.
Renal Impairment
The FDA label states that the extent of renal excretion has not been determined, but recommends caution in dose selection for patients with decreased renal function 1. Unlike hepatic impairment, there is no specific pharmacokinetic data to guide dosing adjustments. A conservative approach would be to start with 25-50 mg doses with careful monitoring, as elderly patients (who often have decreased renal function) are already recommended for low-dose initiation.
Intravenous Administration
Hydroxyzine is NOT approved for intravenous administration 1. The FDA label specifically describes only:
- Intramuscular injection: 50-100 mg for adults in psychiatric emergencies
- Oral administration: Standard route for maintenance therapy
The label emphasizes that intramuscular injections must be given deep into large muscles (upper outer quadrant of buttock or mid-lateral thigh in adults) to avoid significant tissue damage from inadvertent subcutaneous injection 1.
Critical Safety Warnings
Hydroxyzine carries a significant QT prolongation risk and should be used cautiously in patients with cardiac risk factors 1. Post-marketing reports document cases of QT prolongation and Torsade de Pointes, particularly in patients with:
- Pre-existing heart disease
- Electrolyte imbalances
- Concomitant use of other QT-prolonging drugs
- Recent myocardial infarction
- Uncompensated heart failure
When used with CNS depressants (narcotics, barbiturates, alcohol), reduce the dose of concomitant medications by up to 50% 1. The FDA label reports rare cardiac arrests and deaths with combined use of hydroxyzine and other CNS depressants.
Important Clinical Context
Current clinical guidelines do not recommend hydroxyzine as first-line treatment for anxiety. The 2020 NICE guidelines for anxiety management recommend benzodiazepines (lorazepam 0.5-1 mg orally four times daily, reduced to 0.25-0.5 mg in elderly patients) rather than hydroxyzine 6. This represents a significant divergence between FDA-approved indications and contemporary guideline recommendations.
The most common adverse effect is transient drowsiness (28% vs 14% with placebo), which typically appears during the first week and progressively diminishes 3. Recent forensic data shows hydroxyzine can significantly impair driving performance, with observations including incoordination, slurred speech, and difficulty with coordination tasks 7.
Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), requiring immediate discontinuation at first sign of skin rash or hypersensitivity 1.